PILA PHARMA Partners with Gubra for Preclinical Obesity Trials of TRPV1 Inhibitor XEN-D0501
Key Insights
PILA PHARMA (search) has signed a contract with Danish CRO Gubra (search) to conduct preclinical proof-of-concept studies of XEN-D0501 in obese rats.
The 4-week study will test the TRPV1 (search) inhibitor in both DIO and Zucker rat obesity (search) models, with results expected before February 2026.
XEN-D0501 has previously shown statistical significance in enhancing insulin response and reducing cardiovascular biomarkers in Phase 2a trials.
Swedish biotech company PILA PHARMA (search) has entered into a strategic partnership with Danish contract research organization Gubra (search) to conduct preclinical trials of its TRPV1 (search) inhibitor XEN-D0501 in obesity (search) models. The collaboration marks a pivotal step in the company's expansion from diabetes treatment into the obesity therapeutic space.
Study Design and Methodology
The preclinical study will evaluate XEN-D0501's anti-obesity (search) effects over 4 weeks of treatment in two established rat models. The research will utilize both diet-induced obesity (DIO) rats, where normal rats are fed a high-fat diet to induce obesity, and Zucker rats, which develop obesity spontaneously due to a genetic mutation causing overeating on normal diets.
"We're very pleased to now be able to announce the selection of Gubra (search) as our new contract research partner as they came highly recommended by big pharma due to their level of quality," said Founder and CSO Dorte X. Gram. "Generating proof-of-concept in obese rats would put PILA PHARMA (search) in a unique position as a pioneering innovator in the space."
Clinical Development Background
XEN-D0501 has demonstrated promising results in human studies. The company has completed two Phase 2a clinical trials (PP-CT01 and PP-CT02) showing that the drug is well tolerated in people living with obesity (search) and type 2 diabetes (search). In PP-CT02, XEN-D0501 administered as 4 mg twice daily for 28 days showed statistical significance versus placebo in enhancing endogenous insulin response to oral glucose. The trial also demonstrated a highly statistically significant reduction in ANP, a cardiovascular biomarker for heart failure.
The company is currently preparing PP-CT03, a new Phase 2a trial designed to identify the maximal tolerable dose of XEN-D0501 in people with obesity (search) and type 2 diabetes (search), while evaluating safety following 3 months of chronic treatment. This study will include sufficient participants to allow for efficacy readouts on body weight reduction.
TRPV1 Mechanism and Discovery
XEN-D0501 is a selective, synthetic small molecule TRPV1 (search) inhibitor formulated as a simple and stable tablet. The therapeutic principle was discovered by PILA PHARMA (search)'s founder Dorte X. Gram during her PhD studies at Novo Nordisk, where she found that TRPV1 inhibitors could prevent glucose intolerance and body weight gain in spontaneously obese pre-diabetic rats.
TRPV1 (search) inhibitors down-regulate neurogenic inflammation and have demonstrated applications across pain and inflammatory diseases, with potential roles in diabetes and metabolic disorders like obesity (search). The discovery revealed a previously unknown role of TRPV1 in regulating both blood glucose and body weight.
Market Opportunity and Timeline
The obesity (search) market represents a significant therapeutic opportunity, with estimates of more than 1 billion people living with obesity (BMI >30) globally in 2025, and 4 billion people classified as overweight (BMI >27). CEO Gustav H. Gram noted that results are expected before the warrant strike period of February 5-15, 2026, with more detailed timelines to be communicated when the study begins in autumn 2025.
Strategic Positioning
The collaboration with Gubra (search), a specialized preclinical CRO with approximately 275 employees and 2024 revenue of DKK 266 million, enables PILA PHARMA (search) to pursue dual development tracks. The company aims to assess XEN-D0501 in individuals with overweight both with and without type 2 diabetes (search), creating a comprehensive data package to support the drug as a potential first-in-class oral treatment.
Beyond obesity (search) and diabetes, XEN-D0501 has received orphan drug designation for erythromelalgia (search) treatment and has shown preclinical proof-of-concept in reducing abdominal aorta aneurysm (search) growth in mice, demonstrating the compound's broader therapeutic potential across multiple indications.